Business
OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program
The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., Sept. 2, 2020
About this update from Opko Health, Inc.
[{"type":"text","content":"The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment\n\n\nELMWOOD PARK, N.J., Sept. 2, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. \n\n \n \n \n \n \n \n\n \nThrough a strategic collaboration with BioReference, New York City, the Department of Health and New York City Health and Hospital Corporation (NYC Health + Hospitals) will collect specimens from principals, teachers and staff members across eight locations. BioReference will then perform COVID-19 PCR tests for the principals, teachers and other school staff at its Elmwood Park, New Jersey laboratory facility. The hours of operation for collection of specimens will be 8:00 a.m. to 8:00 p.m. ET, Monday through Sunday, beginning today and concluding Monday, September 7. Registration and appointment selection is required. To register for collection of a specimen for a COVID-19 test, visit: https://appointments.bioreference.com/nycschools. \n\"As NYC schools prepare for the upcoming year, COVID-19 testing will play a pivotal role in supporting a safer overall classroom environment for educators, students and their families,\" said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. \"The systematic measures put in place by New York City reaffirm the dedication to safety and education in New York City.\"\nAbout BioReference Laboratories, Inc.BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women's health, maternal fetal medicine, oncol...